Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SE Tylose is a leading global manufacturer of cellulose ethers, headquartered in Wiesbaden, Germany. As a key subsidiary of the Shin-Etsu Group, the company specializes in the production of methylcellulose and hydroxyethylcellulose under the well-known Tylose® brand. Their products are vital to the pharmaceutical industry, where they serve as high-purity excipients for applications such as tablet binding, thickening, and controlled-release drug delivery. Beyond healthcare, SE Tylose provides essential chemical additives for the construction, paint, and personal care industries. The company operates state-of-the-art manufacturing facilities that adhere to strict Global Manufacturing Practice (GMP) standards to ensure the safety and efficacy of their pharmaceutical-grade materials. With a strong focus on research and development, SE Tylose continues to innovate in polymer science to meet the evolving needs of global drug formulators.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SE Tylose.